MIT Corporation elects 10 term members, two life members for 2026

“The MIT Corporation — the Institute’s board of trustees — has elected 10 full-term members, who will serve five-year terms, and two life members. Corporation Chair Mark P. Gorenberg ’76 announced the election results today. The full-term members are: Kate A. Bergeron, Elizabeth Choe, Kevin B. Churchwell, Stephen P. DeFalco, Bennett W. Golub, Pearl S. Huang, Steve Isakowitz, Adrianna C. Ma, Pamela Melroy, and Alex Morcos. The life members are Eran Broshy and Ray A. Rothrock. Gorenberg was also re-elected as Corporation chair. David L. Fung ’85, the 2026-2027 president of the Association of Alumni and Alumnae of MIT, will also join the Corporation as an ex officio member. He succeeds Stephen P. DeFalco ’83, SM ’88. As of July 1, 2026, the Corporation will consist of 75 distinguished leaders in education, science, engineering, and industry. Of those, 22 are life members and eight are ex officio. An additional 33 individuals are life members emeritus. The 10 new term members are: Kate A. Bergeron ’93, MBA ’13 , vice president of hardware engineering at Apple, Inc. Bergeron joined Apple in 2002 as a senior mechanical engineer and has served as vice president of hardware engineering since 2014. Previously, she was senior director for ecosystem products and technologies and senior director of Macintosh product design. Bergeron co-developed the course MIT D-Lab: Design for Scale, which she co-taught from 2013 to 2017. Earlier in her career, she worked as a mechanical engineer at EM Designs and at the Palo Alto Design Group (now Flextronics International Ltd.). She has regularly been named by Business Insider as one of the most powerful female engineers in the world and was elected to the National Academy of Engineers in 2022. Elizabeth Choe ’13, PhD ’25 , director of AI strategy for translational medicine at AstraZeneca At AstraZeneca, Choe oversees the deployment of biomedical deep-learning models for cancer drug development and leads upskilling programs for biologists and clinicians. As an MIT PhD student, she worked on brain cancer therapies at the Koch Institute for Integrative Cancer Research. Between her undergraduate and graduate studies, she worked in digital media in several roles: leading MIT+K12 Videos, producing media for National Geographic and the National Institutes of Health, designing global online teacher training programs at the MIT Media Lab’s Learning Initiative, and serving as assistant director of communications in the Office of Undergraduate Admissions. Throughout her graduate studies, she was actively involved in campus leadership, serving as a graduate resident advisor and participating in the Graduate Student Council, the Presidential Search Committee, and other groups. Kevin B. Churchwell ’83 , CEO of Boston Children’s Hospital At Boston Children’s Hospital, Churchwell leads an organization dedicated to advancing child health through clinical care, research and innovation, medical education, and community engagement. Since joining the hospital in 2013 as chief operating officer and executive vice president of health affairs, he led a transformation that significantly reduced safety events affecting patients and employees. Earlier, Churchwell served as CEO of Nemours/Alfred I. duPont Hospital for Children in Wilmington and CEO and executive director of Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center in Nashville. He is currently a professor of pediatric anesthesia and the Robert and Dana Smith Professor of Anesthesia at Harvard Medical School. Stephen P. DeFalco ’83, SM ’88 , executive chair of Creation Technologies Before assuming his current role, DeFalco served as chairman and CEO at Creation Technologies, an electronics manufacturing services provider, for six years. Prior to that, he was a partner at Lindsay Goldberg Private Equity, following a role as president and CEO of Crane Currency. DeFalco has also held CEO roles at MDS, a global life sciences company; Senseonics, a diabetes care company, where he is still chairman; and PathoGenetix. He was also president of PerkinElmer Instruments, a strategy consultant at McKinsey and Company, and a product development leader at IBM. Bennett W. Golub ’79, SM ’82, PhD ’84 , co-founder of and senior advisor at BlackRock In 1988, Golub was one of eight people to start the global asset management company BlackRock, Inc; he stepped down from his day-to-day activities in 2022 to assume a part-time role of senior policy advisor. Formerly, he served as chief risk officer with responsibilities that included investment, counterparty, technology, and operational risk, and he chaired BlackRock’s Enterprise Risk Management Committee. Beginning in 1995, he was co-head and founder of BlackRock Solutions, the company’s risk advisory business. He also served as the acting CEO of Trepp, LLC. and as vice president at The First Boston Corporation (now Credit Suisse). Pearl S. Huang ’80 , CEO and president of Dunad Therapeutics, Inc. Huang has decades of experience spanning the biotech and pharmaceutical industries, with oversight across early drug discovery and development, translational research, and alliance management. Prior to Dunad, she was CEO and president of Cygnal Therapeutics, founded by Flagship Pioneering, where she was also a venture partner. Earlier, she held leadership roles as senior vice president of therapeutic modalities at Roche; vice president and global head of discovery partnerships with academia at GSK; and vice president, oncology franchise integrator, at Merck. She was also a founder and acting chief scientific officer of Beigene. Steve Isakowitz ’83, SM ’84 , former CEO and president of the Aerospace Corporation Throughout his career, Isakowitz has worked across the public and private sectors to advance U.S. leadership in space. At the Aerospace Corporation, he led a strategic transformation of the organization to address the rapid commercialization of the space sector, the emergence of space as a warfighting domain, and the need for faster, more agile technical execution. Before that, he held leadership positions as chief technology officer at Virgin Galactic, and later president of the company’s space ventures business; chief financial officer at the U.S. Department of Energy; and deputy associate administrator for exploration at NASA. He also served in roles at the Central Intelligence Agency and the White House Office of Management and Budget. Adrianna C. Ma ’95, MEng ’96 , operating partner at Index Ventures At Index Ventures, Ma oversees operations, facilitates the investment process, and is responsible for fundraising and capital partnering. Previously, she was a managing partner of the investment firm the Fremont Group, a managing director of General Atlantic, and a technology mergers and acquisitions banker at Morgan Stanley. At the Fremont Group, she oversaw a portfolio of actively managed funds, public securities, and private co-investments; chaired the investment committee; and assisted with Fremont’s direct private equity investments. During her 10 years at General Atlantic, she led investments in, and served on the boards of, growth-stage technology companies around the world. At Morgan Stanley, she focused on technology-related mergers and acquisitions. Pamela Melroy SM ’84 , president and managing partner of Melroy and Hollett Technology Partners As deputy administrator of NASA, Melroy was responsible for laying the agency’s vision and representing NASA to the executive office of the president and others. Before retiring from the U.S. Air Force in 2007, she logged more than 6,000 flight hours as a co-pilot, aircraft commander, instructor pilot, and test pilot. She is a veteran of Operation Desert Shield/Desert Storm and Operation Just Cause. As a NASA astronaut, Melroy served as pilot on two space shuttle missions and was the mission commander on a third. She later took on a number of leadership roles, including at Lockheed Martin, the U.S. Federal Aviation Administration, the U.S. Defense Advanced Research Projects Agency, and Nova Systems, and as an advisor to the Australian Space Agency. Alex Morcos ’97, ’98, MEng ’98 , co-founder of Chaincode Labs Morcos co-founded Hudson River Trading in 2002, where he spent 10 years helping to build the quantitative trading firm. In 2014, he and fellow co-founder Suhas Daftuar started Chaincode Labs, a research and development center for Bitcoin, with a focus on open-source software and education. Recently, he applied his interest in emerging technologies to help found Fulcrum Science, a public good initiative to use AI to accelerate scientific research. The two new life members are: Eran Broshy ’79 , former CEO and chair of Syneos Health Broshy has spent more than 35 years as a health care executive, building high-growth public and private health care businesses as CEO, board chair, director, strategist, and investor. He served for over a decade as CEO and chairman of Syneous Health (formerly inVentiv Health), taking the company public and turning it into the leading global provider of outsourced clinical and commercial services to pharmaceutical and life sciences companies. Before that, he served as the CEO of the biotechnology platform company Coelacanth Corp, and as a managing partner at The Boston Consulting Group. Since 2010, Broshy has worked in private equity across the health care space globally. Ray A. Rothrock SM ’78 , partner emeritus at Venrock A philanthropist, venture capitalist, and advocate for clean energy, Rothrock spent 25 years at the venture capital firm Venrock, focusing on early-stage investments related to information technology, cybersecurity, and energy. He served as chair of the National Venture Capital Association and as CEO of the cybersecurity technology startup RedSeal, and he previously held management positions at Sun Microsystems. Earlier in his career, Rothrock held various engineering positions at Yankee Atomic Electric, Exxon Minerals, and Sagus. Today, he is a venture partner with Shield Capital and advisor to numerous venture capital firms. He was a member of the U.S. Department of Energy’s Nuclear Energy Advisory Committee, and in the last decade he co-produced several documentary films.

Summary generated from the RSS feed of MIT News. All article rights belong to the original publisher. Click through to read the full piece on news.mit.edu.